Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial | Zendy

E. Sebastian Debus | Zendy; Mark R. Nehler | Zendy; Nicholas Govsyeyev | Zendy; Rupert Bauersachs | Zendy; Sonia S. Anand | Zendy; Manesh R. Patel | Zendy; Fabrizio Fanelli | Zendy; Warren H. Capell | Zendy; Taylor Brackin | Zendy; Franz Hinterreiter | Zendy; Dainis Krieviņš | Zendy; Patrice Nault | Zendy; Gabriele Piffaretti | Zendy; А. В. Светликов | Zendy; Nicole Jaeger | Zendy; Connie N. Hess | Zendy; Henrik Sillesen | Zendy; Michael S. Conte | Zendy; Joseph L. Mills | Zendy; Eva Muehlhofer | Zendy; Lloyd Haskell | Zendy; Scott D. Berkowitz | Zendy; William R. Hiatt | Zendy; Marc P. Bonaca | Zendy

Open Access

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial

Author(s) -

E. Sebastian Debus,

Mark R. Nehler,

Nicholas Govsyeyev,

Rupert Bauersachs,

Sonia S. Anand,

Manesh R. Patel,

Fabrizio Fanelli,

Warren H. Capell,

Taylor Brackin,

Franz Hinterreiter,

Dainis Krieviņš,

Patrice Nault,

Gabriele Piffaretti,

А. В. Светликов,

Nicole Jaeger,

Connie N. Hess,

Henrik Sillesen,

Michael S. Conte,

Joseph L. Mills,

Eva Muehlhofer,

Lloyd Haskell,

Scott D. Berkowitz,

William R. Hiatt,

Marc P. Bonaca

Publication year - 2021

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.121.054835

Subject(s) - medicine , rivaroxaban , aspirin , myocardial infarction , surgery , stroke (engine) , thrombolysis , clinical endpoint , revascularization , randomized controlled trial , hazard ratio , coronary artery disease , warfarin , atrial fibrillation , confidence interval , mechanical engineering , engineering

Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research